Inactive Instrument

Cytori Therapeutics Inc Stock price Nasdaq

Equities

US23283K4022

Biotechnology & Medical Research

Sales 2024 * 3.4M Sales 2025 * 4.28M Capitalization 7.91M
Net income 2024 * -19M Net income 2025 * -22M EV / Sales 2024 * 2.33 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.85 x
P/E ratio 2024 *
-0.81 x
P/E ratio 2025 *
-0.98 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.77%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 61 02-09-30
Director of Finance/CFO 51 20-02-05
Chief Tech/Sci/R&D Officer - 23-07-26
Members of the board TitleAgeSince
Chief Executive Officer 61 02-09-30
Chairman 75 07-11-30
Director/Board Member 75 20-02-29
More insiders
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing treatments for patients battling cancer. The Company develops a targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. Its lead radiotherapeutic candidate, Rhenium (186Re) obisbemeda is designed specifically to CNS cancers including recurrent glioblastoma (GBM), leptomeningeal metastases (LM), and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. The Company's Rhenium (186Re) obisbemeda, a novel injectable radiotherapy designed to deliver targeted, high dose radiation directly into GBM tumors. The Company's portfolio also includes 188RNL-BAM, a radioembolization therapy for liver cancer.
More about the company
  1. Stock
  2. Equities
  3. Stock Plus Therapeutics, Inc.
  4. Stock Cytori Therapeutics Inc - Nasdaq